Antiretroviral therapy in HIV infection: Are neurologically active drugs important?

Archives of Neurology

Volumn 61, Issue 11, 2004, Pages 1699-1704

  Cysique, Lucette A J ^a,c   Maruff, Paul ^b   Brew, Bruce J ^c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b LA TROBE UNIVERSITY   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEMORY; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH SURVEYS; HIV INFECTIONS; HUMANS; MALE; MEMORY DISORDERS; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; OUTPATIENT CLINICS, HOSPITAL; VIRAL LOAD;

EID: 7744226571     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.61.11.1699     Document Type: Article

References (22)

1. Sacktor N, McDermott M, Marder K, et al. HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol. 2002;8:136-142.
2. Enting R, Hoetelmans R, Lange J, et al. Antiretroviral drugs and the central nervous system. AIDS. 1998;12:1941-1953.
3. Polis MA, Suzman DL, Yoder CP, et al. Suppression of cerebrospinal fluid HIV burden in antiretroviral naive patients on a potent four-drug antiretroviral regimen. AIDS 2003;17:1167-1172.
4. Brew BJ, Brown SJ, Catalan J, et al. Safety and efficacy of abacavir (ABC, 1952) in AIDS dementia complex (Study CNAB 3001). In: Program and abstracts of the 12th World AIDS Conference; June 28-July 3, 1998; Geneva, Switzerland. Abstract 561/32192.
5. Sidtis JJ, Gatsonis C, Price RW, et al. Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. Ann Neurol. 1993;33:343-349.
6. Sacktor N, Tarwater PM, Skolasky RL, et al. CSF antiretroviral drug penetrance and the treatment of HIV-associated psychomotor slowing. Neurology. 2001; 57:542-544.
7. Marra CM, Lockhart D, Zunt JR, et al. Changes in CSF and plasma HIV-1 RNA and cognition after starting potent antiretroviral therapy. Neurology. 2003; 60:1388-1390.
8. Huisman MT, Smit JW, Crommentuyn KML, et al. Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS. 2002;16:2295-2301.
9. Hsu A, Granneman GR, Bertz RJ. Ritonavir: clinical and pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet. 1998;35:275-291.
10. Veni PG, Hammer SM, Carpenter CCJ, et al. Antiretroviral treatment for adult HIV infection m 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA. 2002;288:222-235.
11. Gulick RM, Staszewski S. New drugs for HIV therapy. AIDS. 2002;16(suppl 4): S135-S144.
12. Antinori A, Giancola ML, Grisetti S, et al. Factors influencing virological response to antiretroviral drugs in cerebrospinal fluid of advanced HIV-1-infected patients. AIDS. 2002;16:1867-1876.
13. Butters N, Grant I, Haxby J. Assessment of AIDS-related cognitive changes: recommendations of the NIMH Workgroup on Neuropsychological Assessment Approaches. J Clin Exp Neuropsychol. 1990;12:963-978.
14. Lovibond SH, Lovibond PF. Manual for the Depression Anxiety Stress Scales. 2nd ed. Sydney, Australia: Psychology Foundation; 1995.
15. Howell DC. Statistical Methods for Psychology. 5th ed. Pacific Grove, Calif: Thomson Learning; 2002.
16. Grunseit AC, Perdices M, Dunbar N, Cooper DA. Neuropsychological function in asymptomatic HIV-1 infection: methodological issues. J Clin Exp Neuropsychol. 1994;16:898-910.
17. Perneger TV. What's wrong with Bonferroni adjustments. BMJ. 1998;316:1236-1238.
18. Mannheimer S, Friedland G, Matts J, et al. The consistency of adherence to antiretrovlral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis. 2002;34:1115-1121.
19. Reger M, Wesh R, Razani J, et al. A meta-analysis of the neuropsychological sequelae of HIV infection. J Int Neuropsychol Soc. 2002;8:410-424.
20. Sacktor NC, Bacellar H, Hoover DR, et al. Psychomotor slowing in HIV infection: a predictor of dementia, AIDS and death. J Neurovirol. 1996;2:404-410.
21. Ferrando SJ, Rabkin JG, van Gorp WG, et al. Longitudinal improvement in psychomotor processing is associated with potent antiretroviral therapy in HIV-1 infection. J Neuropsychiatry Clin Neurosci. 2003;15:208-214.
22. Brew BJ. Evidence for a change in AIDS dementia complex in the era of highly active antiretroviral therapy and the possibility of new forms of AIDS dementia complex. AIDS. 2004;18(suppl 1):S75-S78.